840 Memorial Drive
Entrance on Blackstone Street, Third Floor
About AxcellaAxcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass.
CEO: Robert Connelly
CMO: Christopher I. Wright
CFO: Thomas Leggett
Please click here for Axcella job opportunities.
17 articles with Axcella
Axcella Health Inc. announced financial results for the second quarter ended June 30, 2019 and provided a company update.
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
Axcella to Present Late-Breaker Data on Lead AXA™ Candidate, AXA1665 at EASL, the International Liver Congress™
Axcella Health announced a late-breaker poster presentation for their novel endogenous metabolic modulator composition, AXA1665 in subjects with mild and moderate hepatic insufficiency.
Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways
Data further support compositions of Endogenous Metabolic Modulators (EMM) as novel multifactorial assets with the potential to support health or become therapeutically relevant
Axcella Health Inc. (the “Company,” “Axcella,” or “we”), a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the 37th Annual JP Morgan Healthcare Conference, taking place January 7-10, 2019, at the Westin St. Francis Hotel in San Francisco, CA.
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression.
Dr. Mitchener brings 15 years of pharmaceutical industry experience driving domestic and international commercialization, BD&L, operations, and value creation to Axcella.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
Mr. Hinshaw is a highly accomplished health care executive with nearly three decades of global pharmaceutical experience and was most recently Executive Vice President and Head of U.S. Oncology at Novartis.
Axcella Announces The Appointment Of Ivana Magovcevic-Liebisch, Ph.D., J.D., As Executive Vice President, Chief Strategy And Corporate Development Officer